TGTX Q2 2021 Earnings — TG Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TGTXTG Therapeutics, Inc.

$5B

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M+3965.8% YoY

Gross Profit

$1M90.4% margin

Operating Income

-$77M-5015.7% margin

Net Income

-$78M-5080.7% margin

EPS (Diluted)

$-0.59

QoQ Revenue Growth

+94.8%

Cash Flow

Operating Cash Flow

-$60M

Free Cash Flow

-$60M

Stock-Based Comp.

$16M

Balance Sheet

Total Assets

$481M

Total Liabilities

$98M

Stockholders' Equity

$383M

Cash & Equivalents

$402M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$38,000	+3965.8%
Gross Profit	$1M	$38,000	+3576.3%
Operating Income	-$77M	-$51M	-52.4%
Net Income	-$78M	-$53M	-48.4%

Revenue Segments

Product

$2M98%

License

$38,0002%